Exsilio Therapeutics, a Boston, MA-based biotechnology company developing genomic medicines for a broad range of diseases, raised $82M in Series A funding.
The round was led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Tal Zaks, Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Its technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates.
Exsilio uses predictive in silicomodeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells.
Commenting on the news, Tal Zaks, said: “Exsilio’s approach leverages the advantages of mRNA and goes a step further by encoding genes that integrate permanently, offering the possibility of curative rather than transient effects. The ability to insert whole genes with a repeatable and titratable approach should allow us to treat genetic diseases irrespective of the patient’s individual mutation. This financing will help us advance our genomic medicines and select promising lead candidates so that we can bring much-needed new options to patients.”
FinSMEs
25/06/2024